WOCKPHARMA - Wockhardt
📢 Recent Corporate Announcements
Wockhardt Limited has been assigned an overall ESG rating of 65, categorized as 'Aspiring,' for the year 2025 by NSE Sustainability Ratings and Analytics Limited. The score is derived from individual ratings of 51 for Environmental, 70 for Social, and 74 for Governance parameters. This assessment was conducted voluntarily by the SEBI-registered provider based on public disclosures, without a formal engagement by the company. The relatively high Governance score of 74 highlights the company's focus on transparency and corporate oversight.
- Assigned an overall ESG score of 65 for the year 2025 by a SEBI-registered provider.
- Governance score of 74 and Social score of 70 outperform the Environmental score of 51.
- Rating was independently determined by NSE Sustainability Ratings using public information.
- The 'Aspiring' status indicates a commitment to ESG progress and disclosure standards.
Wockhardt reported a strong financial performance for Q3 FY26, with revenue growing 22% YoY to ₹888 crore. EBITDA saw a significant jump of 72% to ₹173 crore, with margins expanding to 19.5% from 13.8% in the previous year. Profit After Tax (PAT) improved to ₹61 crore compared to ₹20 crore in Q3 FY25. The growth was primarily driven by a 96% surge in Biotech operations and robust performance in Emerging Markets and the India Branded Business.
- Revenue increased 22% YoY to ₹888 crore; EBITDA grew 72% to ₹173 crore.
- Biotech segment revenue reached ₹213 crore, with Emerging Market biotech growing over 50%.
- India Branded Business grew 28% to ₹146 crore, aided by Diabetic therapy and NCE (EMROK).
- Novel antibiotic Zaynich received EMA Accelerated Assessment; Foviscu successfully met Phase 3 endpoints.
- Exceptional items of ₹107 crore for 9M FY26 include impacts from US entity liquidation and the New Labour code.
Wockhardt Limited reported a strong year-on-year performance for the quarter ended December 31, 2025, with standalone revenue growing 32% to ₹430 crore. The company achieved a standalone net profit of ₹28 crore, marking a significant turnaround from a loss of ₹22 crore in the same quarter last year. For the nine-month period ending December 2025, the company has turned profitable with a net profit of ₹150 crore compared to a loss of ₹52 crore in the previous year. Profitability for the quarter was slightly impacted by a ₹10 crore exceptional charge related to the new Indian Labour Code compliance.
- Standalone revenue from operations increased 32.3% YoY to ₹430 crore from ₹325 crore.
- Reported a standalone net profit of ₹28 crore vs a loss of ₹22 crore in the year-ago period.
- Nine-month standalone net profit reached ₹150 crore, a sharp recovery from a ₹52 crore loss in the prior year.
- Recognized an exceptional charge of ₹10 crore due to the impact of consolidated Labour Codes.
- Basic EPS for the nine-month period improved to ₹9.24 compared to a negative ₹3.36 in the previous year.
Dr. Sanjeev Kumar Sharma, the President of Manufacturing, Quality & R&D at Wockhardt Limited, has resigned from his position effective February 2, 2026. As a designated Senior Management Personnel (SMP), his departure impacts three critical pillars of the company's operations. The resignation is attributed to personal reasons, and he will cease to be an SMP of the company. Investors should note that this role is vital for maintaining regulatory standards and product development pipelines.
- Dr. Sanjeev Kumar Sharma resigned as President - Manufacturing, Quality & R&D effective February 2, 2026.
- The official reason provided for the resignation is personal reasons.
- The role is classified as Senior Management Personnel (SMP) under SEBI Listing Regulations.
- The departure covers oversight of three major departments: Manufacturing, Quality, and R&D.
Wockhardt has announced that its fifth novel antibiotic, Foviscu (WCK 4282), successfully met its primary endpoint in a pivotal Phase 3 trial for treating complicated urinary tract infections. The drug demonstrated a clinical cure rate of 93.23%, matching the 92.31% achieved by the gold-standard meropenem, while showing a well-tolerated safety profile. This milestone is significant as it addresses high-resistance ESBL pathogens in a market where approximately 65 lakh treatment courses of similar antibiotics are used annually in India. The drug has already received QIDP designation from the US FDA, enhancing its global commercial potential.
- Foviscu achieved a 93.23% clinical cure rate versus 92.31% for the gold-standard meropenem in Phase 3 trials.
- This is Wockhardt's 5th proprietary antibiotic to successfully complete a registration-enabling Phase 3 study.
- The trial targeted ESBL-producing pathogens, which accounted for 51.4% of the Enterobacterales isolates in the study.
- Foviscu addresses a large domestic market where 65 lakh treatment courses of similar antibiotics are used annually.
- The product holds US FDA Qualified Infectious Disease Product (QIDP) status, providing regulatory advantages.
Wockhardt Limited has been assigned an ESG (Environmental, Social, and Governance) rating of 70 for the year 2025. This rating was voluntarily assigned by CFC Finlease Private Limited, a SEBI-licensed ESG rating provider, based on the company's public disclosures. Importantly, the company clarified that it did not engage or commission the agency for this assessment, making it an independent third-party evaluation. Such ratings are becoming increasingly significant for institutional investors who prioritize sustainability and governance metrics.
- Assigned an ESG rating of 70 for the year 2025 by a SEBI-licensed provider.
- The rating was determined independently by CFC Finlease Private Limited based on public information.
- Wockhardt did not engage or pay the rating agency for this specific assessment.
- The disclosure is made in compliance with SEBI Listing Obligations and Disclosure Requirements.
Wockhardt Limited has filed the mandatory compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the quarter ended December 31, 2025. The certificate, issued by the Registrar MUFG Intime India Private Limited, confirms that all dematerialization requests were processed within the legal timeframe. It ensures that physical share certificates were properly cancelled and the register of members was updated accordingly. This filing is a standard administrative requirement for all listed entities in India to ensure the integrity of electronic shareholding.
- Compliance certificate submitted for the quarter ended December 31, 2025.
- Registrar MUFG Intime India confirmed processing of all dematerialization requests within prescribed timelines.
- Securities comprised in the certificates are confirmed to be listed on BSE and NSE.
- Physical certificates were mutilated and cancelled after due verification by the depository participant.
Wockhardt has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic WCK 5222 (Zaynich®) on January 5, 2026. The EMA has granted the drug 'Accelerated Assessment' status, which will shorten the review timeline across 30 European countries including the EU and EEA. This follows a successful global Phase III trial and a previous NDA filing with the US FDA under fast-track review. As the first Indian-developed New Chemical Entity (NCE) to seek pan-European approval, this marks a major commercial milestone for the company's R&D pipeline.
- WCK 5222 filed with EMA for marketing authorization across 30 European countries on January 5, 2026.
- Granted 'Accelerated Assessment' by EMA, allowing for an abridged review period due to high unmet medical needs.
- The drug is a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g) targeting multi-drug resistant infections.
- WCK 5222 is already under fast-track review by the US FDA and has been filed with Indian regulatory authorities.
- Wockhardt's portfolio includes 6 antibiotics with US FDA QIDP designation, supporting its 77% international revenue base.
Wockhardt Limited has been assigned an ESG rating of 73, categorized as 'Excellent', for the year 2025. The rating was voluntarily issued by ESG Risk Assessments & Insights Limited, a SEBI-registered provider, based on the company's public disclosures. Significantly, the company did not commission this report, indicating an independent validation of its sustainability and governance practices. This high score may improve the company's standing with ESG-focused institutional investors.
- Assigned an ESG rating of 73 for the year 2025.
- Rating categorized as 'Excellent' by a SEBI-registered ESG rating provider.
- Assessment was voluntary and independent, not commissioned by Wockhardt.
- Rating is based on public disclosures and publicly available information.
Wockhardt Limited has been assigned an ESG rating of 67.3 for the financial year 2024-25 by SES ESG Research Pvt Ltd, a SEBI-registered provider. This rating was assigned voluntarily and independently by the research firm based on the company's public disclosures. The company clarified that it did not engage or pay for this specific assessment, highlighting its transparency in public reporting. ESG ratings are becoming increasingly relevant for institutional investors and funds that prioritize sustainable and ethical business practices.
- SES ESG Research assigned an ESG rating of 67.3 for the 2024-25 financial year.
- The rating was determined independently based on publicly available information and disclosures.
- Wockhardt Limited did not formally engage the provider for this specific rating process.
- SES ESG Research is a SEBI-registered ESG rating provider, ensuring regulatory compliance in its assessment.
Wockhardt Limited has received a tax demand order from the Central GST Range in Ghaziabad for the financial year 2019-20. The total demand amounts to ₹90,23,518, which includes a penalty component of ₹28,07,984. The demand arose due to adjustments in GST returns related to excess taxes paid in earlier years. The company has stated that it will file an appeal and that the order has no material impact on its financial or operational activities.
- Total tax demand of ₹90,23,518 received from GST authorities in Ghaziabad for FY 2019-20.
- The demand includes a penalty of ₹28,07,984.
- The issue pertains to GST adjustments made for excess taxes paid during previous years.
- Wockhardt intends to file an appeal against the order to contest the demand.
- Management confirms the order has no material impact on the company's financials or operations.
The European Medicines Agency (EMA) has granted Accelerated Assessment to Wockhardt's novel antibiotic WCK 5222 (Zaynich®), which targets multi-drug resistant Gram-negative infections. This designation is reserved for drugs addressing unmet medical needs and will significantly speed up the review process for pan-European marketing authorization. WCK 5222 has already completed global Phase III trials and has pending applications with the USFDA and Indian regulators. This marks the first time an Indian-discovered New Chemical Entity (NCE) is being submitted for such authorization in Europe.
- EMA grants Accelerated Assessment for WCK 5222 (Zidebactam 1g + Cefepime 2g) to treat life-threatening MDR/XDR infections.
- WCK 5222 is the first Indian-discovered NCE submitted for pan-European marketing authorization.
- Global Phase III clinical trials are complete, with NDA already filed and accepted by the USFDA.
- Wockhardt's pipeline includes 6 antibiotics with USFDA QIDP designation, with 77% of revenue coming from international markets.
Wockhardt Limited has announced the closure of its trading window for all designated persons starting January 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the announcement of the unaudited financial results for the quarter ending December 31, 2025. The window will remain closed until 48 hours after the results are declared. This is a standard regulatory procedure for listed companies in India to prevent insider trading.
- Trading window closure effective from January 1, 2026
- Closure pertains to the Unaudited Financial Results for the quarter ended December 31, 2025
- Window will reopen 48 hours after the official declaration of results
- Complies with SEBI (Prohibition of Insider Trading) Regulations, 2015
Wockhardt Ltd. announced that the US FDA has accepted the New Drug Application (NDA) for its antibiotic Zaynich, marking the first time an Indian pharmaceutical company has achieved this milestone for a New Chemical Entity (NCE). The NDA was filed on September 30, 2025. Zaynich has received Fast Track designation from the FDA, potentially expediting the review process. This acceptance highlights Wockhardt's innovation and could lead to significant revenue opportunities if the drug is approved.
- US FDA accepts Wockhardt’s New Drug Application for Zaynich
- First-ever NDA Acceptance for an Indian Pharmaceutical Company
- NDA was originally filed on September 30, 2025
- Zaynich has been granted Fast Track designation by the US FDA
- Wockhardt initiated Zaynich development program in 2011
Financial Performance
Revenue Growth by Segment
The Domestic Business grew by 11% YoY, while the Rest of the World (ROW) business recorded a 12% growth. UK operations also reflected a healthy 12% growth, whereas EU operations remained stagnant (0% growth) during FY2025.
Geographic Revenue Split
The UK is the largest contributor at 39% of total revenue. India and Emerging Markets each contribute 23%, while the European Union (excluding UK/Ireland) accounts for 12% of the revenue mix as of FY2025.
Profitability Margins
Gross margins improved as material consumption dropped from 40.4% to 37.3% of revenue. Net profit margin showed a remarkable recovery, improving from -16.1% in FY2024 to -1.5% in FY2025, driven by an exit from low-margin US generics and cost rationalization.
EBITDA Margin
EBITDA margin improved significantly to 13.1% (INR 418 Cr) in FY2025 from 6.1% (INR 251 Cr) in FY2024, representing a 67% YoY growth in EBITDA value due to a shift toward high-margin New Chemical Entities (NCEs).
Capital Expenditure
The company has planned a capital expenditure of INR 300 Cr for FY2026 and INR 250 Cr for FY2027, primarily funded by QIP proceeds and incremental term debt to double manufacturing capacity within 24-36 months.
Credit Rating & Borrowing
ICRA upgraded the rating to [ICRA]BBB- with a Positive outlook. Interest costs as a percentage of sales fell by 2.2% YoY following deleveraging; the interest coverage ratio improved to 1.5 times in FY2025 from 0.6 times in FY2024.
Operational Drivers
Raw Materials
Active Pharmaceutical Ingredients (API) and Key Starting Materials (KSM) represent the primary raw material costs, which accounted for 37.3% of total revenue in FY2025, down from 40.4% in the previous year.
Capacity Expansion
Wockhardt currently operates 12 manufacturing facilities globally. The company is planning to double its capacity in the next 24 to 36 months to support the $3 billion opportunity in the diabetes portfolio (Insulin Glargine and Aspart).
Raw Material Costs
Raw material costs (material consumption) stood at 37.3% of revenue in FY2025. The company achieved a 3.1% reduction in material costs through portfolio swings in favor of high-margin segments and better procurement hygiene.
Manufacturing Efficiency
Average utilization of sanctioned working capital limits declined sharply to 31% post-November 2024 QIP, compared to 92.5% in the April-October 2024 period, indicating significantly improved capital efficiency.
Logistics & Distribution
Other expenditures, which include distribution and administrative costs, were rationalized to 24.7% of revenue in FY2025 from 25.9% in FY2024.
Strategic Growth
Expected Growth Rate
20%
Growth Strategy
Growth will be driven by the launch of novel antibiotics like MIQNAF (launched May 2025) and ZAYNICH, which targets a $9 billion global market. Additionally, the company is targeting a 20% growth in the biosimilars segment in emerging markets and plans to double production capacity for its $3 billion diabetes portfolio within 3 years.
Products & Services
The company sells finished dosage formulations, vaccines, biotechnology products (Insulin), and New Chemical Entities (NCEs) such as antibiotics for respiratory and skin infections.
Brand Portfolio
ZAYNICH, MIQNAF, Emrok, Emrok O, Insulin Glargine, and Aspart.
New Products/Services
MIQNAF was launched in May 2025 with an addressable Indian market of INR 10,800 Cr. WCK 5222 is filed for approval in India and expected to be filed in the US by August 2025.
Market Expansion
Targeting expansion in Emerging Markets, the US, and Europe with the novel antibiotic portfolio and doubling capacity for diabetes products in the next 24-36 months.
External Factors
Industry Trends
The industry is shifting from simple generics to complex biosimilars and NCEs. Wockhardt is positioning itself as a research-driven multinational, moving its R&D spend to 11.2% of revenue to lead in the antibiotic resistance (AMR) therapeutic area.
Competitive Landscape
Faces intense competition from both global MNCs and Indian generic players, leading to pricing pressure in regulated markets.
Competitive Moat
The moat is built on a portfolio of 6 antibiotics with USFDA QIDP status, providing 5 years of market exclusivity post-approval. This patent-backed drug discovery program is a durable advantage against generic competitors.
Macro Economic Sensitivity
The company is highly sensitive to government intervention regarding price caps and controls in the pharmaceutical sector, which can directly limit revenue growth in the domestic market.
Consumer Behavior
Increasing global unmet need for antibiotics to treat drug-resistant pathogens is driving demand for Wockhardt's NCE portfolio.
Geopolitical Risks
Operations in multiple countries (India, UK, Ireland, US) expose the company to changes in import/export policies and environmental/regulatory shifts in those specific jurisdictions.
Regulatory & Governance
Industry Regulations
The company must comply with strict US FDA and international standards; it currently has outstanding import alerts and warning letters for some manufacturing facilities which remain a key monitorable.
Environmental Compliance
Wockhardt is exposed to tightening environmental regulations regarding waste and pollution norms, which could increase capital investment requirements for manufacturing compliance.
Taxation Policy Impact
The effective tax rate was 1.4% of revenue in FY2025. The company faces ongoing tax disputes with various departments, though the total value has reduced from the previous year.
Legal Contingencies
The company has 'sizeable' contingent liabilities and ongoing tax disputes as of March 31, 2025. Specific INR values for these cases are not disclosed in the provided documents.
Risk Analysis
Key Uncertainties
The success of NCE molecules (like WCK 5222 and WCK 4282) is critical; failure in clinical trials or lack of market adoption could jeopardize the recovery in profitability metrics.
Geographic Concentration Risk
High concentration in the UK market, which accounts for 39% of total revenue, making the company vulnerable to UK-specific regulatory or economic shifts.
Third Party Dependencies
The company relies on third-party manufacturers for its US market supply, creating a dependency on external production quality and timelines.
Technology Obsolescence Risk
The drug discovery team (145 members) is tasked with preventing obsolescence by developing next-generation antibiotics to combat evolving bacterial resistance.
Credit & Counterparty Risk
Receivables quality is supported by an improved liquidity position following the INR 1,000 Cr QIP, which reduced reliance on high-cost working capital (utilization down to 31%).